Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, comments on the challenges of interpreting the results of genomic tests in chronic lymphocytic leukemia (CLL), highlighting the need for quality control, particularly with next-generation sequencing (NGS) methods. Prof. Cymbalista also discusses the importance of communicating the results from these tests to patients in an understandable way. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.